Last reviewed 2026-05-14 · How we verify

Inactive Poliovirus Vaccine

Inactive Poliovirus Vaccine stimulates the immune system to produce antibodies against all three serotypes of poliovirus without causing disease.

Inactive Poliovirus Vaccine stimulates the immune system to produce antibodies against all three serotypes of poliovirus without causing disease. Used for Prevention of poliomyelitis caused by poliovirus types 1, 2, and 3.

At a glance

Mechanism of action

The vaccine contains chemically inactivated (killed) poliovirus particles that trigger humoral and cellular immune responses, leading to the production of neutralizing antibodies against poliovirus types 1, 2, and 3. This provides protection against poliomyelitis infection through immunological memory without the risk of vaccine-derived poliovirus that can occur with live attenuated vaccines.

Approved indications

• Prevention of poliomyelitis caused by poliovirus types 1, 2, and 3

Common side effects

• Injection site pain, erythema, or swelling
• Fever
• Myalgia or fatigue
• Headache

Key clinical trials

• Clinical Trial of Novel OPV2 Vaccine (PHASE2)
• Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan (PHASE4)
• Study of SP059 Given Subcutaneously as a Three-dose Primary and Booster Vaccination in Infants in Japan (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Inactive Poliovirus Vaccine CI brief — competitive landscape report
• Inactive Poliovirus Vaccine updates RSS · CI watch RSS
• Sanofi Pasteur, a Sanofi Company portfolio CI